Coronado partner stops mid-stage study of bowel disease treatment

(Reuters) - Coronado Biosciences Inc said its German partner discontinued a mid-stage study of its inflammatory bowel disease treatment due to lack of effectiveness. The news comes about three weeks after Coronado said the treatment, Trichuris suis ova, failed to meet the main goal of a mid-stage study. The company said on Thursday that its partner, Dr. Falk Pharma GmbH, discontinued the study on the recommendation of an independent data monitoring committee. Coronado said the committee analyzed data from a trial in Europe by Falk Pharma on patients with Crohn's disease, a type of inflammatory bowel disease.



via Health News Headlines - Yahoo! News http://news.yahoo.com/coronado-partner-stops-mid-stage-study-bowel-disease-121359188--finance.html